Effects of dietary corn bran hemicellulose and neomycin on hepatic caspase-3 activity and glycoprotein concentration in rats treated with or without D-galactosamine.
The effects of dietary corn bran hemicellulose (CBH) and neomycin (Neo) on hepatic caspase-3 activity and glycoprotein concentration were investigated to explore the possible mechanism of the alleviative action of dietary CBH and Neo on the development of D-galactosamine (GalN)-hepatitis. Rats were fed a diet containing 5% CBH with or without neomycin (Neo) for 7 or 14 d. On the last day of feeding, the rats were treated with GalN (400 mg/kg body weight, i.p.), and their plasma transaminase activities, hepatic glycoprotein concentrations and hepatic caspase-3 activities were determined 6 or 24 h later. Although the elevations of plasma transaminase activities were suppressed by CBH or Neo 24 h after GalN-treatment, the activities were not affected by CBH or Neo at an early stage (6 h) of GalN action. At 6 h, hepatic caspase-3 activity was elevated by CBH diet alone as high as that of the GalN-injected control-diet group, and the activity was not elevated further by GalN. At the same time, both GalN-treatment and CBH feeding reduced the hepatic glycoprotein (Mw. 64,000-74,000) concentration, but Neo did not affect the caspase activity or the glycoprotein concentration. These results suggest that dietary CBH elevates hepatic caspase-3 activity and reduces hepatic glycoprotein concentration, and may imply that CBH would suppress GalN-hepatitis not at the early- or middle-step of apoptosis but at the late-step of apoptosis or necrosis, although the relation between these phenomena and the alleviative effects of CBH and Neo on GalN-induced hepatitis is yet to be clarified.
Daizo
Ayako
A
Seitoku University, Chiba, Japan. daizo@seitoku.ac.jp
Egashira
Yukari
Y
Sanada
Hiroo
H
D000821:Animal Feed; D000818:Animals; D053148:Caspase 3 / Q000378:metabolism*; D019610:Cytoprotection / Q000187:drug effects; D004032:Diet; D005688:Galactosamine / Q000494:pharmacology*; D006023:Glycoproteins / Q000097:blood*; D006505:Hepatitis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D009355:Neomycin / Q000008:administration & dosage / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D011134:Polysaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D000637:Transaminases / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects; D003313:Zea mays
D006023:Glycoproteins; D011134:Polysaccharides; D005688:Galactosamine; C007916:hemicellulose; D000637:Transaminases; D053148:Caspase 3; D009355:Neomycin